IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells
AUTOR(ES)
Klebanoff, Christopher A.
FONTE
National Academy of Sciences
RESUMO
IL-15 and IL-2 possess similar properties, including the ability to induce T cell proliferation. However, whereas IL-2 can promote apoptosis and limit CD8+ memory T cell survival and proliferation, IL-15 helps maintain a memory CD8+ T cell population and can inhibit apoptosis. We sought to determine whether IL-15 could enhance the in vivo function of tumor/self-reactive CD8+ T cells by using a T cell receptor transgenic mouse (pmel-1) whose CD8+ T cells recognize an epitope derived from the self/melanoma antigen gp100. By removing endogenous IL-15 by using tumor-bearing IL-15 knockout hosts or supplementing IL-15 by means of exogenous administration, as a component of culture media or as a transgene expressed by adoptively transferred T cells, we demonstrate that IL-15 can improve the in vivo antitumor activity of adoptively transferred CD8+ T cells. These results provide several avenues for improving adoptive immunotherapy of cancer in patients.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=357036Documentos Relacionados
- Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination
- IL-15 mimics T cell receptor crosslinking in the induction of cellular proliferation, gene expression, and cytotoxicity in CD8+ memory T cells
- IL-15/IL-15Rα-mediated avidity maturation of memory CD8+ T cells
- CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer
- Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells
